---
title: "Avalo Therapeutics (AVTX) Gets a Buy from BTIG"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295226150.md"
description: "BTIG analyst Julian Harrison maintained a Buy rating on Avalo Therapeutics (AVTX) with a $58 price target, while H.C. Wainwright also issued a Buy rating with a $30 target. The stock closed at $18.70. Analyst consensus remains a Strong Buy with an average target of $43.78, implying significant upside."
datetime: "2026-08-07T11:16:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295226150.md)
  - [en](https://longbridge.com/en/news/295226150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295226150.md)
generator: "portal-rs"
---

# Avalo Therapeutics (AVTX) Gets a Buy from BTIG

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Avalo Therapeutics, with a price target of $58.00. The company’s shares closed yesterday at $18.70.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Harrison is a top 100 analyst with an average return of 53.6% and a 57.38% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Liquidia Technologies, and Innoviva.

Currently, the analyst consensus on Avalo Therapeutics is a Strong Buy with an average price target of $43.78, which is a 134.12% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $30.00 price target.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [INVA.US](https://longbridge.com/en/quote/INVA.US.md)

## Related News & Research

- [Avalo Therapeutics (NASDAQ:AVTX) Insider Sells 679 Shares of Stock](https://longbridge.com/en/news/297701048.md)
- [Avalo Therapeutics CMO Mittie Doyle sells 679 common shares for $13,580](https://longbridge.com/en/news/297696537.md)
- [Avalo Therapeutics grants 78,000 inducement stock options priced at $19.34 per share](https://longbridge.com/en/news/298071367.md)
- [Avalo Therapeutics management participates in Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297902386.md)
- [Morgan Stanley Remains a Buy on Rockwell Automation (ROK)](https://longbridge.com/en/news/297785354.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**